Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
Status:
Completed
Trial end date:
2018-04-28
Target enrollment:
Participant gender:
Summary
This is an open-label, single-sequence, 3-period crossover study conducted in healthy
subjects. Eligible subjects will participate in a single treatment period, in which they will
receive the following treatments: Day 1, single doses of midazolam and metoprolol; Day 2,
single doses of pioglitazone, tolbutamide, and omeprazole; Days 5 to 17, daily doses of
relacorilant; Day 14, single doses of midazolam and metoprolol (with relacorilant); and, Day
15, single doses of pioglitazone, tolbutamide, and omeprazole (with relacorilant).